In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
|Articles|March 28, 2022
FDA May Authorize Second Booster Doses for Both mRNA Vaccines Soon
Author(s)John Parkinson
The federal agency is expected to provide the EUAs prior to their next VRBPAC meeting on April 6.
Advertisement
It has been reported that the Food and Drug Administration will give both Moderna and Pfizer Emergency Use Authorizations (EUA) for a second booster dose of their COVID-19 vaccines for adults 50 years and older, according to a report in the NY Times.
The decision is expected to happen prior to the next Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting on April 6, according Eric Topol, MD, director of the Scripps Translational Research Institute San Diego.
Earlier this month, both
At this moment in time, public health officials, clinicians, scientists, and others have mixed opinions on whether the second booster dose in people over 50 is warranted.
In addition, the mRNA vaccines’ effectiveness has been
The VRBPAC meeting’s agenda includes the following topics:
- What might warrant updating the composition of COVID-19 vaccines to address specific variants.
- Timing and populations for COVID-19 vaccine booster doses in the coming months.
The FDA noted that no vote is planned for the meeting and that they would not be discussing any product-specific applications.
Advertisement
Related to this article
A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
Advertisement
Advertisement